申请人:Sonoke Satoru
公开号:US20110098344A1
公开(公告)日:2011-04-28
A drug carrier characterized by mainly containing a polyethylene-glycol-modified phospholipid and a cationic lipid and containing the polyethylene-glycol-modified phospholipid in a concentration within a specific range. The drug carrier, which is of the in-blood residence type, is characterized by comprising a polyethylene-glycol-modified phospholipid represented by the following general formula (I) or a pharmaceutically acceptable salt thereof:
[wherein X represents the following (II) or (III) and n is an integer of 30-150]
[wherein R
1
represents a saturated linear C
17-22
fatty acid residue] and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglylcerol. It is further characterized in that the polyethylene-glycol-modified phospholipid represented by the general formula (I) is contained in an amount of 30-50 wt. % based on the total amount of the lipids in the drug carrier.
一种药物载体,其主要包含聚乙二醇修饰的磷脂和阳离子脂质,并且聚乙二醇修饰的磷脂的浓度在特定范围内。该药物载体属于血内驻留型,其特征在于包含以下通式(I)表示的聚乙二醇修饰的磷脂或其药学上可接受的盐:[其中X表示以下(II)或(III),n是30-150的整数][其中R1表示饱和线性C17-22脂肪酸残基]和2-O-(2-二乙氨乙基)氨基甲酰基-1,3-O-二油酰基甘油。它进一步特征在于,根据药物载体中脂质的总量,聚乙二醇修饰的磷脂的含量为30-50重量%。